SGLT2 inhibitors are a class of medications approved for use in type 2 diabetes to treat hyperglycemia. Patients with HFrEF typically receive therapy with loop diuretics, considered the standard kind of diuretics. SGLT2i have demonstrated the capability to reduce the likelihood of hospitalisation for heart failure (HF), independent of diabetes status. It has also presented a reduced pace of decrease in the estimated glomerular filtration rate (GFR). These findings are backed by many trials. Renal assessments from certain clinical trials offer further confirmation that SGLT2 inhibitors possess kidney-protective effects, leading to a notably decreased risk of advancing to macroalbuminuria or experiencing clinically significant renal outcomes, such as doubling of serum creatinine levels and the need for renal replacement therapy. SGLT2 inhibitors possess the potential to exacerbate the diuretic impact of traditional treatments, which might result in a decrease in volume. On the contrary, considering SGLT2 inhibitors exert a minimal diuretic effect, they are unlikely to have an enormous effect on the strong action of loop diuretics. The effects of SGLT2 inhibitor administration to HFrEF who were already on sacubitril/valsartan were investigated in a different study. According to this investigation, the combination of the aforementioned drugs could assist patients with HFrEF have even fewer instances of morbidity and death. 

Numerous investigations have exhibited the possible therapeutic effectiveness of SGLT2i in the management of cardiovascular events via diverse methods. However, the impact of SGLT2i on the dosage of loop diuretics and sacubitril/valsartan while treating heart failure patients who are on background diuretics and sacubitril/valsartan has not been well studied. Therefore, further research must be done to fully comprehend this process. This study intends to investigate the impact of SGLT2i on loop diuretic and sacubitril/valsartan dose in heart failure patients already on diuretics and sacubitril/valsartan and scrutinize the shift in loop diuretic dose and sacubitril/valsartan over a certain period.